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Access to essential medicines is problematic for one third of all persons worldwide. 
The price of many medicines (i.e., drugs, vaccines, and diagnostics) is unaffordable 
to the majority of the population in need, especially in least-developed countries, but 
also increasingly in middle-income countries. Several innovative approaches, based on 
partnerships, intellectual property, and pricing, are used to stimulate innovation, promote 
healthcare delivery, and reduce global health disparities. No single approach suffices, and 
therefore stakeholders need to further engage in partnerships promoting knowledge 
and technology transfer in assuring essential medicines to be manufactured, authorized, 
and distributed in low- and middle-income countries (LMICs) in an effort of making them 
available at affordable and acceptable conditions.
Keywords: public–private partnership, product development partnership, intellectual property, pricing mechanism, 
access to healthcare
INTRODUCTION
Today’s healthcare systems, both in developed and developing countries, face serious challenges. 
And time is pressing; in the years to come, we will face a dramatic shift in health problems resulting 
from epidemiological transition (1, 2). The poorest countries in developing regions carry the highest 
burden of disease: communicable diseases (CDs), non-communicable diseases (NCDs) (3), and the 
risk of new diseases related to changes in the social and physical environment, the socio-behavioral 
illness (4).
Access to essential medicines is problematic for one third of all persons worldwide (5). The price 
of many medicines (i.e., drugs, vaccines, and diagnostics) is unaffordable to the population in need, 
Abbreviations: APOC, African Programme for Onchocerciasis Control; BMGF, Bill & Melinda Gates Foundation; CD, com-
municable diseases; DNDi, drugs for neglected diseases initiative; EC, European Commission; EFPIA, European Federation of 
Pharmaceutical Industries and Associations; ELF, European Lead Factory; GAVI, global alliance for vaccines and immuniza-
tions; GCP, good clinical practice; GSK, GlaxoSmithKline; IMI, innovative medicines initiative; IP, intellectual property; IGO, 
international governmental organizations; IPRs, IP rights; IPTK bank, intellectual property, technology and know-how bank; 
LMIC, low- and middle-income countries; MA, market authorization; mHealth, mobile health application; MMV, medicines 
for malaria venture; MPP, medicines patent pool; NCD, non-communicable diseases; NGO, non-governmental organizations; 
NTD, neglected tropical diseases; OWH, Institute for One World Health; PDP, product development partnership; PPP, pub-
lic–private partnership; R&D, research and development; TPP, Trans-Pacific Partnership; TRIPS, agreement on trade-related 
aspects of intellectual property rights; TTIP, Transatlantic Trade and Investment Partnership; UN, United Nations; WHO, 
World Health Organization; WIPO, World Intellectual Property Organization; WTO, World Trade Organization.
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especially in the least-developed countries, but also increasingly 
in middle-income countries. The latter category comprises 105 
countries, accounting for 70% of the world population, 75% of 
the poor, and a majority of the global disease burden (6, 7). Prices 
may decrease when multiple companies need to share market, in 
which context overcoming intellectual property (IP) obstacles is 
essential (8).
Stakeholders bundle forces in assuring essential medicines 
are manufactured, authorized, and distributed in low- and 
middle-income countries (LMICs) at affordable conditions. But 
challenges remain, i.e., guaranteeing high distribution coverage, 
ensuring affordability, and adoption of essential medicines, both 
at provider level and end-user level (9). Developing countries 
lack infrastructure needed to increase access to medicines. Most 
diagnostics are not designed for implementation in non-optimal 
laboratory conditions present in developing countries, with lack 
of air conditioning, stable electrical power, or refrigerators to store 
samples and chemicals (10, 11). Through microfluidic systems, 
high-tech technologies could find their way to the developing 
world laboratories. But the need for faster and more accurate 
diagnostics remains (10).
This article provides an overview of innovative approaches by 
stakeholders to address health challenges in developing countries, 
shedding light on business models for healthcare delivery. We 
look at the role of partnerships, IP, and specific pricing models 
for promoting innovation by providing incentives to invest in 
(collaborative) research and development (R&D), as well as to 
increase access to medicines.
METHOD
A comprehensive review of literature was performed. Relevant 
articles were identified by searching databases, such as PubMed, 
Google Scholar, and documents like Official Journal of the 
European Union (EUR-Lex) up to March 2016, with an update 
in September 2017. Websites of relevant organizations, including 
public-private partnerships (PPPs) such as the innovative medicines 
initiative (IMI) and the medicines for malaria venture (MMV), 
pharmaceutical organizations’ websites, such as GlaxoSmithKline 
(GSK) and European Federation of Pharmaceutical Industries 
and Associations (EFPIA), and non-governmental organizations’ 
websites and private foundations’ websites, such as World Health 
Organization (WHO), World Intellectual Property Organization 
(WIPO), World Trade Organization (WTO), and Bill & Melinda 
Gates Foundation (BMGF), were explored.
PARTNERSHIPS AS A MODEL TO 
FACILITATE ACCESS TO MEDICINES
Pharmaceutical companies no longer stick to traditional drug 
development models to tackle the enormous health challenges 
ahead of us. Being the key player in the drug development process, 
the pharmaceutical industry is partially responsible for finding 
solutions. During the last decades, the majority of the 20 largest 
research-based pharmaceutical companies have increased efforts 
to provide access to essential medicines in developing countries 
(12), e.g., by supporting or participating in product development 
partnerships (PDPs) (9).
Historically, PDPs directed toward neglected tropical diseases 
(NTDs) were the first collaborative efforts to tackle inequities 
in the health sector. In 1987, Merck & Co. donated ivermectin 
(Mectizan®) to treat onchocerciasis or river blindness, first dis-
tributed by the African Programme for Onchocerciasis Control 
(APOC), a partnership between the World Bank, the WHO, and 
non-governmental organizations (NGOs) in West-Africa, and 
expanded later to Africa and America (13, 14).
Product development partnerships, such as the MMV, have 
served as a source of inspiration for the pharmaceutical industry 
to apply the PPP model to disease areas other than NTDs, such as 
NCDs. The IMI, driven by EFPIA and supported by the European 
Commission (EC), has been a flagship early-phase research PPP 
(15). Initially, IMI focused on NCDs, but as the PPP matures, it 
aims at tackling NTDs (14). The European Lead Factory (ELF), 
for example, explicitly waives certain fees related to non-profit 
drug discovery programs for NTDs (16).
Public–private partnerships, and PDPs in particular, are 
vehicles suitable for delivering healthcare and strengthening 
healthcare systems. Such multi-stakeholder efforts are able 
to ensure product registration, increase local production and 
distribution capacity, and ensure governance for global health, 
e.g., adoption of new health technologies in national treatment 
policies in disease-endemic countries. In this way, PDPs such as 
the MMV, Drugs for Neglected Diseases Initiative (DNDi), and 
Institute for One World Health (OWH), advance public health 
(17, 18). PDPs strengthen research capacity in LMICs by building 
infrastructures at trial sites, providing equipment and setting up 
training in good clinical practice (GCP) and dedicated disease-
specific research platforms in endemic countries. To achieve its 
objectives, PDPs partner with different stakeholders, such as 
high-income country pharmaceutical companies, local manufac-
turers, national disease-specific control programs and platforms, 
national governments and philanthropic organizations (9).
Public–private partnerships leverage knowledge and technol-
ogy transfer of new medical technologies to both developed and 
developing countries. For example, the mobile health applica-
tion (mHealth) Text4Baby, providing free health information 
to expectant mothers by means of text messages, is a PPP that, 
through a network of hundreds of partners, scales up its services 
(19). Partnerships could improve the scale of knowledge and 
technology transfer capacity of African Institutions that prove 
to be leaders in their area of focus (20). PPPs can improve both 
health products and services delivery by scaling their programs to 
a national level, involving health workers and communities (21). 
mHealth strategies are linked to improved data collection and 
reporting, planning and decision-support, training, and overall 
improved communication (22).
Moreover, knowledge and technology transfer should happen 
in both directions. Completely rethinking business models or 
applying reverse innovation requires adequate examination of 
models applied in developing countries in the context of devel-
oped countries. The technology applied in low-resource programs 
can stimulate innovation in developed countries, for example, by 
using text messages and interactive voice recognition systems 
3Stevens and Huys Innovative Approaches to Increase Access to Medicines in Developing Countries
Frontiers in Medicine | www.frontiersin.org December 2017 | Volume 4 | Article 218
instead of smartphone applications or by targeting the markets of 
the underserved such as elderly or immigrant communities (19). 
In this way, an innovation continuum can exist.
IP AS A TOOL TO FACILITATE ACCESS  
TO MEDICINES
A robust IP framework is perceived by most right holders as 
essential to guarantee contribution to the state of the art while 
maintaining control over how creations, protected by IP rights 
(IPRs), are used. As such, IPRs have a facilitating role for improved 
healthcare in developing countries and should not be perceived 
as a hindrance. In pharma, patents are considered as the most 
important IP protection tools, providing the owner exclusive 
rights to prevent use of the patented product or process without 
the consent of the owner for 20 years in a particular territory. Data 
protection and market exclusivity rights are IPRs granted to the 
market authorization (MA) holder for a period of 8, 10 (or 11) 
years, respectively, after MA. Generic or biosimilar products are 
not allowed to enter the market as long as such IPRs are in force.
In many cases, at the time of product launch on the market, 
at least half of the patent term may have expired. Accordingly, 
industry claims to prolong the period of protection for their 
medical inventions (23). In theory, an increase of the period for 
patent and data or market exclusivity can increase profits, which 
may lead to innovation if appropriately re-invested in R&D. 
However, there is no any evidence that innovation thrives when 
extending exclusivity terms. In addition, generics are relied upon 
by most developing countries. Potential consequences of imple-
menting prolonged exclusivity periods in developing countries 
could be enormous. Some propose that revenues from extended 
patent terms could be considered as a source of funding for drug 
donations to the least-developed countries (24).
One major issue is to guarantee that patent protection for 
pharmaceutical products creates incentives for R&D and does not 
hinder patient access in developing countries. The Agreement on 
Trade-Related Aspects of Intellectual Property Rights (TRIPS) of 
the WTO, implemented in 2005, created on the one hand incen-
tives for R&D by introducing minimum standards for protection 
of IP. On the other hand, it introduces some flexibility such as 
compulsory licenses whereby access to IP protected technologies 
is granted via licenses imposed by governments, based on specific 
criteria, for instance, public health reasons. The members at the 
Doha Ministerial Conference in November 2001 agreed upon 
exemptions to patent protection in least-developed countries till 
2016, with a potential extension to 2033 (25, 26).
With respect to compulsory licensing, some LMICs, not able 
to produce new drugs, could invoke such licensing and hence 
rely on capabilities of a developed country. Some state that com-
pulsory licensing may cause consequences on other markets, as 
lower pricing of a compulsory licensed drug may trigger parallel 
export of the cheaper drug into more expensive markets.
The issuing of compulsory licenses gives a certain level of 
autonomy to Southern countries, but implies a certain legal, 
administrative, and reputational cost. In addition, some firms 
believe that compulsory licensing diminishes their incentives for 
innovation (11). Nonetheless, the overall impact of compulsory 
licensing seems beneficial (27). The TRIPS Agreement created 
an environment legitimizing innovators and generic companies, 
stimulating cross-border alliances, increasing numbers of R&D 
alliances, patent filings, and R&D investment. The main issue 
remains the impact of TRIPS on drug pricing and on biophar-
maceutical companies’ willingness to invest in health problems 
at the local level (28).
Measures included in trade and investment agreements, 
e.g., the much debated Transatlantic Trade and Investment 
Partnership (TTIP) or the Trans-Pacific Partnership (TPP) agree-
ments, impose far-reaching IP standards favoring the monopoly 
of large drug producers: extending patent terms, lowering patent-
ability criteria, data/market exclusivity preventing generic and 
biosimilar drugs to enter the market, data protection obligations 
for biologics enabling high prices of e.g., cancer biologic drugs to 
remain longer on the market and routes to block generic drugs 
from entering the country. These provisions, called the TRIPS-
Plus provisions, can, when translated effectively into domestic law, 
disproportionately affect developing countries by leading to high 
prices for essential medicines. To this end, policy makers have 
a crucial role in negotiation of policies and regulations (29, 30).
Other IP mechanisms relevant in the access debate are patent 
pools. The medicines patent pool (MPP) aims to enable afford-
able production of HIV drugs still under patent protection by 
obtaining voluntary licenses from patent holders and making 
these licenses available to generic companies in LMICs. Royalties 
will be paid to patent holders, and licenses to generic companies 
will be offered only in LMICs (8).
Another initiative in this line is an intellectual property, technol-
ogy and know-how (IPTK) bank, a single platform licensed as a 
package with associated training modules. The IPTK bank could 
offer assistance in navigating vaccine registration with national 
regulatory authorities. The licensing approach covers patented 
technology to be disseminated to multiple developing-countries 
vaccine makers and royalties paid to the patent holder. IPTK 
banks would require an initial period of funding until provision of 
affordable vaccines would render them to be self-sustainable (8). 
Currently, the main source of external funding for vaccines in low-
income countries is the global alliance for vaccines and immuniza-
tions (GAVI) (11). The subsidies provided by GAVI to finance new 
vaccines in a response to the 2012 World Health Assembly Global 
Vaccine Action Plan are intended to be limited to a 5-year period, 
with the expectation that, over that time, prices will fall, allowing 
donors and national governments to continue vaccine financing. 
Unfortunately, to date, this expectation has not been realized. There 
remains a need to establish mechanisms ensuring sustainable vac-
cine pricing once the initial period of support has ended (8).
The WHO report “Research and Development to Meet Health 
Needs in Developing Countries” considered several policies/
models for access to medicines. The first model is a global 
framework on R&D, supporting priority medical R&D aimed at 
addressing neglected diseases. This model is not meant to replace 
the current IPR system, but is an additional instrument to meet 
the R&D needs of developing countries (31). The second model is 
a proposal that deals with open approaches to R&D, such as open 
innovation, open source, open access publishing, precompetitive 
R&D platforms, and equitable licensing (32).
FIGURE 1 | Link between intellectual property (IP) frameworks as defined in the IP policies of the public–private partnership (PPPs) analyzed, the information 
provided in the IP policies, project focus, and project deliverables. PPPs are categorized by research focus [non-communicable diseases (NCDs, circles), 
communicable diseases (CDs, squares), or a mix (triangles)]; availability of IP information [unavailable (gray outlines) and limited, partial, or substantial availability 
(black outlines)]; and deliverables [research tools and platform technologies (striped shading), drugs, diagnostic, and therapeutic tools or materials (dotted shading) 
or a mix (no shading)]. ADNI, Alzheimer’s Disease Neuroimaging Initiative; BioWin, Biotechnologies Wallonie Innovation; CTMM, Center for Translational Molecular 
Medicine; DNDi, Drugs for Neglected Diseases Initiative; FP7, European Framework Programmes; IMI, innovative medicines initiative; MMV, medicines for malaria 
venture; ND, not disclosed by PPP request; OAI, Osteoarthritis Initiative; OMOP, Observational Medical Outcomes Partnership; OSDD, Open Source Drug 
Discovery; SC4SM, Stem Cells for Safer Medicines; TSC, the SNP Consortium; TRC, the RNAi Consortium; SGC, Structural Genomics Consortium. [Figure adapted 
from Stevens et al. (34) with permission from the authors.]
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In both proposed models, there is a need for flexible application 
of IPRs to reduce IP hurdles for innovation, which may reduce 
duplication in research and contribute to capacity-building, 
knowledge, and technology transfer (32). The WHO also covers 
the ethical dimension and the myriad of economic, commercial, 
technological, and regulatory factors related to providing health-
care, particularly to the poor (33).
Several types of IP strategies can be adopted in these two mod-
els, depending on the type of partnership. In partnerships focused 
on CDs, a partnership-focused strategy is adopted whereby IP is 
preserved for project partners. In partnerships focused on devel-
oping diagnostic devices or on NCDs, often an open collabora-
tion strategy is used, whereby IP is shared with a broad research 
community. There might also be a hybrid strategy, wherein the IP 
framework applied is negotiated on a case-by-case basis. In any 
case, much ambiguity remains about the type of IP strategy most 
suitable, calling for transparency and explicitness in IP policies 
(34) (Figure 1). Ideally, public and private partners complement 
each other in many ways. Both the public partner, such as NGOs 
or international governmental organizations (IGOs), and indus-
try deploy IP, trade, and rules of competition. However, there is 
a difference in their market, mission, and strategy. The public 
partner serves as balancing force for the competitive advantages 
of industry (35).
PRICING MODELS TO FACILITATE 
ACCESS TO MEDICINES
Increased access to essential medicines can be established by 
prolonging patent terms whereby the revenues are reinvested 
for drug donations (24). However, the donor model (e.g., the 
Mectizan Donation Program) has also encountered criticism. 
Long-term drug donations are unsustainable due to a lack of 
infrastructure for technical, economic, and political support (35).
Especially the production of low-cost medicines and distri-
bution thereof is challenging. Specific financing mechanisms 
stimulate price reductions of essential medicines leading to rapid 
uptake. The Global Fund’s Affordable Medicines Facility for 
Malaria, for example, is set up to provide significant subsidies to 
the private sector, as a large portion of people access medicines 
primarily through private markets (9). Furthermore, generic 
competitors and trade regulations are key to driving prices down, 
requiring involvement of multi-sectoral global governance agen-
cies, such as the WTO.
Differential or tiered pricing means selling essential medicines 
in LMICs at prices below those in industrialized countries (36). 
In order to avoid parallel trade (export) of low-priced drugs to 
high-income countries, contracts including confidential rebates 
are used. This concept gained attention in the profit as well as 
non-profit sector since setting a product price to consumers’ 
willingness or ability to pay seems to be a profit maximizing 
strategy. At the same time, tiered pricing can increase consum-
ers’ welfare by creating access to medicines. Yet tiered pricing 
does not guarantee a price that is equitable or affordable (37). 
In addition, generic prices are generally lower than tiered prices. 
Furthermore, tiered prices will unlikely be reduced in case 
of absence of competition, on the contrary, tiered prices may 
increase when competition does arise.
Off-patent competition results in prices below those in a tiered 
pricing setting. But tiered pricing may lead to anticompetitive 
effects when a very low tiered price discourages market entry 
by potential competitors. It is in situations of low demand and 
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production capacity that tiered pricing by a single producer 
in developing countries may result in the widest access. Some 
difficulties remain with tiered pricing: what is the “lowest price 
possible,” what is a “fair price,” and how to negotiate if own pro-
duction capacity is not favorable. In this sense, market segmenta-
tion needs to be considered both across and even within national 
markets (38).
However, income-related price discrimination and competi-
tion alone may not lead to affordable prices in low-income coun-
tries (39). Because of skewed income distributions in LMICs, drug 
prices with respect to mean per capita income are the highest in 
the poorest countries. Generic prices are below originator prices 
but because of lack of regulatory requirements for generic quality 
in LMIC, the latter is heterogeneous and uncertain to consumers. 
The optimal pricing strategy of a manufacturer is based on the 
type of product and on consumer’ perceptions and willingness to 
pay for that product with a particular quality. Procurement pro-
cedures rely on minimum quality standards. They also introduce 
originator and generic prices compared with the counterpart 
retail pharmacy prices and may reduce uncertainty related to 
quality, hence focusing competition on price (39).
CONCLUSION
Several mechanisms, based on partnerships, IP, and pricing, are 
used to promote healthcare delivery and reduction of global health 
disparities. The mechanisms applied involve mostly existing drugs 
and devices that have lost their economic value in developed 
countries. Besides investigating how access mechanisms currently 
used could be enhanced, there is obviously a need to increase 
research for NTDs. Supported by strong leadership and actions at 
national or regional level, the United Nations (UN) commitments 
on the “25 by 25 goal,” i.e., a 25% reduction in premature NCDs 
mortality by 2025, can be achieved (40). Organizations such as 
WHO, WIPO, and WTO have a leading role in designing policies 
applicable to the various stakeholders. A critical mass of strong 
leaders in science, policy making, financing, and education are 
pivotal in building an innovation continuum.
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